Discover undervalued stocks with Eulerpool.

Subscribe for $2

Gilead Sciences Stock GILD

Price

0
Today +/-
-0
Today %
-0 %

Gilead Sciences stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Gilead Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Gilead Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Gilead Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Gilead Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Gilead Sciences Stock Price History

DateGilead Sciences Price
9/25/20250 undefined
9/24/2025112.35 undefined
9/24/2025113.67 undefined
9/23/2025114.70 undefined
9/22/2025112.50 undefined
9/19/2025114.10 undefined
9/18/2025113.63 undefined
9/17/2025112.27 undefined
9/16/2025111.16 undefined
9/15/2025112.33 undefined
9/12/2025115.01 undefined
9/12/2025115.25 undefined
9/11/2025117.48 undefined
9/10/2025115.26 undefined
9/9/2025115.77 undefined
9/8/2025115.05 undefined
9/5/2025115.06 undefined
9/4/2025112.67 undefined
9/3/2025112.81 undefined
9/2/2025112.74 undefined
8/29/2025112.91 undefined
8/29/2025112.91 undefined
8/28/2025112.57 undefined
8/27/2025113.93 undefined

Gilead Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Gilead Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Gilead Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Gilead Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Gilead Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Gilead Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Gilead Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Gilead Sciences’s growth potential.

Gilead Sciences Revenue, EBIT and net profit per share

DateGilead Sciences RevenueGilead Sciences EBITGilead Sciences Net Income
2030e36.88 B undefined0 undefined14.93 B undefined
2029e35.24 B undefined17.09 B undefined13.92 B undefined
2028e33.63 B undefined16.14 B undefined12.68 B undefined
2027e32.23 B undefined15.43 B undefined11.95 B undefined
2026e30.51 B undefined14.28 B undefined11 B undefined
2025e29.35 B undefined13.47 B undefined10.37 B undefined
202428.75 B undefined10.83 B undefined480 M undefined
202327.12 B undefined9.86 B undefined5.67 B undefined
202227.28 B undefined10.03 B undefined4.59 B undefined
202127.31 B undefined9.92 B undefined6.23 B undefined
202024.69 B undefined4.07 B undefined123 M undefined
201922.45 B undefined4.46 B undefined5.39 B undefined
201822.13 B undefined8.37 B undefined5.46 B undefined
201726.11 B undefined14.39 B undefined4.63 B undefined
201630.39 B undefined18.47 B undefined13.5 B undefined
201532.64 B undefined22.19 B undefined18.11 B undefined
201424.89 B undefined15.38 B undefined12.1 B undefined
201311.2 B undefined4.59 B undefined3.08 B undefined
20129.7 B undefined4.01 B undefined2.59 B undefined
20118.39 B undefined3.86 B undefined2.8 B undefined
20107.95 B undefined4.14 B undefined2.9 B undefined
20097.01 B undefined3.59 B undefined2.64 B undefined
20085.34 B undefined2.69 B undefined1.98 B undefined
20074.23 B undefined2.17 B undefined1.59 B undefined
20063.03 B undefined1.64 B undefined-1.19 B undefined
20052.03 B undefined1.11 B undefined814 M undefined

Gilead Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000.0100.030.130.150.170.20.230.470.871.332.033.034.235.347.017.958.399.711.224.8932.6430.3926.1122.1322.4524.6927.3127.2827.1228.7529.3530.5132.2333.6335.2436.88
-200.0033.33-25.00-40.001,000.00300.0014.3911.9215.9819.3999.5785.8752.6553.0649.2139.7926.1531.3913.385.4815.7215.45122.1931.13-6.89-14.09-15.241.469.9810.60-0.09-0.606.042.073.955.634.364.784.66
100.00100.00100.00100.00100.00100.00100.0084.0984.7782.2582.6581.2085.0186.9887.4087.1885.6981.8278.8877.2576.4974.6774.5274.4884.7887.7385.9883.2678.0779.1881.4875.8279.2677.8078.2676.6773.7669.8366.9163.8661.02
00000.0100.030.110.130.140.160.190.40.761.161.772.593.464.215.426.086.267.238.3421.128.6326.1321.7417.2717.7720.1220.721.6221.122.5000000
-0-0.01-0.01-0.03-0.03-0.03-0.02-0.07-0.05-0.07-0.060.050.07-0.070.450.81-1.191.591.982.642.92.82.593.0812.118.1113.54.635.465.390.126.234.595.670.4810.371111.9512.6813.9214.93
-25.00180.0085.7119.23-12.90-18.52231.82-38.3646.67-13.64-191.2338.46-200.00-723.6181.29-246.19-233.1924.8633.2010.05-3.34-7.5618.63293.5349.64-25.44-65.7217.87-1.26-97.724,960.98-26.2323.37-91.532,060.006.078.656.159.747.29
-------------------------1.721.842.082.282.522.722.842.923.003.083.1652.0445.1551.6658.3859.96
000000000000000000000000000.010.010.010.010.01000001.55-0.010.010.010
0.320.360.510.60.610.680.891.261.311.371.461.621.651.611.861.91.841.931.921.871.751.581.581.71.651.521.361.321.311.281.261.261.261.261.26000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Gilead Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Gilead Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                   
0.110.140.120.090.160.30.320.350.290.510.580.940.711.252.310.941.171.791.662.19.91.862.1310.1314.6111.925.5130.0924.357.416.526.397.269.99
00000000.040.050.050.070.130.240.370.40.610.81.021.391.621.951.752.184.645.854.513.853.333.584.894.494.784.664.42
00000000000500000000000000000000000
00000000.020.020.020.040.050.10.140.220.560.60.931.051.21.391.751.71.391.961.590.80.810.921.681.621.511.791.71
0000000.020.010.010.010.010.020.230.090.170.320.460.540.710.780.680.80.991.572.351.591.661.611.442.012.141.772.373.05
0.110.140.120.090.160.30.340.420.370.60.711.181.271.853.092.433.034.284.815.7113.926.16717.7124.7619.5931.8235.8430.31614.7714.4416.0919.17
00.010.010.010.010.010.010.050.050.060.060.070.20.220.240.360.450.530.70.70.771.11.171.672.282.873.34.015.175.615.665.485.325.41
0000000000000000.451.551.452.253.220.060.720.441.611.620.511.191.421.490.51.311.251.160
0000000000000000000000000000000000
0000000000000000001.060.891.0611.7411.911.0710.258.9717.115.7413.7933.1333.4628.8926.4519.95
000000000000000000.120.460.5311.061.171.171.171.174.164.124.128.118.338.318.318.31
00000000.020.010.030.020.040.090.080.430.840.810.560.410.540.480.470.911.431.663.892.712.566.775.064.424.84.796.15
00.010.010.010.010.010.010.070.060.080.090.110.290.310.681.662.812.664.895.883.3815.0815.5816.9526.9537.3938.4627.8431.3352.4153.1848.7346.0439.82
0.110.150.130.10.170.310.350.490.440.680.791.291.562.163.774.095.836.949.711.5917.321.2422.5834.6651.7256.9870.2863.6861.6368.4167.9563.1762.1359
                                                                   
0000000000000001111112221111111111
0.120.170.170.170.270.430.480.720.750.860.90.951.451.892.212.73.213.934.384.654.95.645.392.390.440.451.262.283.053.884.665.556.57.7
-0.01-0.03-0.05-0.09-0.11-0.13-0.16-0.38-0.45-0.51-0.45-0.38-0.45-00.81-0.890.250.321.181.783.716.1112.731818.1519.0119.0219.3914.3816.3215.6916.311.5
-2-3-2-2-1-10-1-3-1723-19112-441-61485-53-136289104294-2913284-62873533132
000000000000000000017-2781212-16-16194-5212-4-33-50
0.110.140.120.090.150.290.320.330.30.350.450.5711.873.031.823.464.276.375.866.749.311.3715.4318.5318.8920.4421.3922.5318.221.0721.2422.8319.33
00000000.010.010.010.020.020.040.050.070.370.290.60.810.81.211.331.260.961.181.210.810.790.710.840.710.910.550.83
000.010.010.010.010.020.040.030.040.060.070.150.180.220.330.420.530.770.911.191.572.254.087.267.787.276.886.257.27.67.17.727.71
0000000.0100.01000.010.010.030.110.040.030.090.290.110.120.170.210.240.470.240.80.190.290.61.790.961.211.65
0000000000000000000000000000000000
00000000.010000000.060.0200.010.010.6501.172.70.480.9802.752.752.52.761.522.271.81.82
00.010.010.010.010.020.030.060.050.060.080.110.190.250.470.760.741.221.872.472.524.246.415.769.899.2211.6410.619.7611.411.6111.2411.2812
0000.010000.090.090.250.250.60.35001.31.31.11.162.847.617.06411.9421.0826.3530.824.5722.0928.6525.1822.9623.1924.9
0000000000000000000000.010.080.050000004.362.671.590.72
00000000.010.010.020.010.020.020.030.270.150.20.150.170.170.320.390.341.11.642.057.356.967.1210.145.745.13.322.13
0000.010000.10.090.270.260.610.370.030.271.451.51.251.323.017.927.464.4313.0822.7128.438.1531.5429.2238.7935.2830.7328.127.75
00.010.010.020.010.020.040.160.140.330.340.720.550.290.742.222.232.473.195.4710.4411.710.8318.8532.637.6149.7842.1438.9850.1946.8941.9639.3839.75
0.110.150.130.10.170.310.350.490.440.680.791.291.552.163.774.035.696.749.5611.3417.182122.234.2751.1456.570.2263.5361.568.3967.9663.262.2159.08
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Gilead Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Gilead Sciences's financial health and stability.

Assets

Gilead Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Gilead Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Gilead Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Gilead Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (B)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
19901991199219931994null19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0-0.01-0.01-0.03-0.03-0.03-0.03-0.02-0.07-0.05-0.07-0.060.050.07-0.070.450.81-1.191.581.972.632.892.792.573.0612.0618.1113.494.645.465.360.096.24.570
000000000.020.010.010.010.020.010.020.020.040.050.10.160.210.270.30.280.351.051.11.161.291.431.41.482.052.12.69
00000000000000-250152-53-9113-25-421264-39-98-236-393-119-82289-2,098-214-116-1,552-962
00000000-0.010-0.02-0.01-0.03-0.04-0.1-0.13-0.25-0.29-0.33-0.130.03-0.680.220.18-0.56-0.521.51.555.11-0.94-0.8-1.640.49-1.76-2.3
000000000.01-0.020.010.01-0.160.020.640.010.162.660.210.320.430.550.460.410.620.821.331.351.583.015.919.093.46.363.73
0000000000.010.010.010.010.010.020.0100.020.010.010.010.02-0.060.250.240.330.530.891.041.070.980.950.980.910.89
000000000000000.010.040.150.490.570.50.751.13-0.621.11.052.063.142.443.343.21.792.642.513.143.99
-0-0-0.01-0.02-0.03-0.03-0.02-0.02-0.05-0.05-0.06-0.04-0.130.070.240.510.711.221.672.143.082.833.643.23.1112.8221.2517.0511.98.49.148.1711.389.078.01
0-1-4-3-4-4-1-4-14-11-12-16-26-18-162-51-48-105-79-115-230-62-132-397-191-557-747-748-590-924-825-650-579-728-585
0-0.02-0.120.030.040.04-0.07-0.04-0.140.07-0.02-0.080.020.05-0.73-0.49-0.68-1.74-1.3-0.18-2.22-1.943.59-11.85-0.25-1.82-12.48-11.99-16.0714.36-7.82-14.62-3.13-2.47-2.27
0-0.02-0.120.040.040.04-0.07-0.04-0.130.08-0-0.070.050.06-0.57-0.44-0.64-1.63-1.22-0.06-1.99-1.883.72-11.45-0.06-1.27-11.73-11.24-15.4815.28-6.99-13.97-2.55-1.74-1.68
00000000000000000000000000000000000
000000-000.06-0.01-0.010.24-00.34-000.30.7-0.1-0-0.012.094.010.52-1.675.679.694.277.17-6.25-2.755.68-4.75-1.5-0.27
810047111921605520293036518479143-142-244-1,723-776-3,646-2,171-201-269-5,018-9,683-10,793-720-2,611-1,540-1,327-377-1,087-768
0.010.10.0500.010.010.090.160.110.010.020.270.030.390.080.080.440.65-0.17-1.48-1.05-1.341.760.56-2.54-3.03-5.88-9.733.39-12.32-7.630.77-8.88-6.47-5.13
0000000000000000095173253-270213-74245-609-3,677-4,016-745-330-486-122-138-145-173-278
00000000000000000000000000-1,874-2,455-2,731-2,971-3,222-3,449-3,605-3,709-3,809
0.010.08-0.090.010.020.02-00.11-0.080.03-0.050.15-0.070.49-0.420.090.430.110.150.49-0.19-0.378.98-8.080.317.912.82-4.62-0.6410.35-6.31-5.63-0.660.070.67
-2-5-13-25-310-24-20-68-62-75-54-15356734576581,1131,5902,0282,8502,7723,5072,7982,91412,26120,50316,29911,3087,4768,3197,51810,8058,3447,421
00000000000000000000000000000000000

Gilead Sciences stock margins

The Gilead Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gilead Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gilead Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Gilead Sciences's sales revenue. A higher gross margin percentage indicates that the Gilead Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Gilead Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Gilead Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Gilead Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Gilead Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Gilead Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Gilead Sciences Margin History

Gilead Sciences Gross marginGilead Sciences Profit marginGilead Sciences EBIT marginGilead Sciences Profit margin
2030e78.26 %0 %40.49 %
2029e78.26 %48.48 %39.5 %
2028e78.26 %47.97 %37.71 %
2027e78.26 %47.87 %37.08 %
2026e78.26 %46.81 %36.05 %
2025e78.26 %45.91 %35.33 %
202478.26 %37.66 %1.67 %
202377.8 %36.37 %20.89 %
202279.26 %36.77 %16.83 %
202175.82 %36.32 %22.8 %
202081.48 %16.49 %0.5 %
201979.18 %19.86 %23.99 %
201878.07 %37.84 %24.65 %
201783.26 %55.13 %17.73 %
201685.98 %60.76 %44.43 %
201587.73 %67.98 %55.48 %
201484.78 %61.8 %48.62 %
201374.48 %40.99 %27.45 %
201274.52 %41.33 %26.71 %
201174.67 %46.08 %33.44 %
201076.49 %52.06 %36.5 %
200977.25 %51.19 %37.6 %
200878.88 %50.41 %37.09 %
200781.82 %51.18 %37.47 %
200685.69 %54.03 %-39.33 %
200587.18 %54.78 %40.14 %

Gilead Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Gilead Sciences earnings per share therefore indicates how much revenue Gilead Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gilead Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gilead Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gilead Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gilead Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Gilead Sciences Revenue, EBIT and net profit per share

DateGilead Sciences Sales per ShareGilead Sciences EBIT per shareGilead Sciences Earnings per Share
2030e29.39 undefined0 undefined11.9 undefined
2029e28.08 undefined0 undefined11.09 undefined
2028e26.8 undefined0 undefined10.11 undefined
2027e25.68 undefined0 undefined9.52 undefined
2026e24.31 undefined0 undefined8.76 undefined
2025e23.39 undefined0 undefined8.26 undefined
202422.91 undefined8.63 undefined0.38 undefined
202321.55 undefined7.84 undefined4.5 undefined
202221.62 undefined7.95 undefined3.64 undefined
202121.64 undefined7.86 undefined4.93 undefined
202019.55 undefined3.22 undefined0.1 undefined
201917.58 undefined3.49 undefined4.22 undefined
201816.92 undefined6.4 undefined4.17 undefined
201719.79 undefined10.91 undefined3.51 undefined
201622.38 undefined13.6 undefined9.94 undefined
201521.46 undefined14.59 undefined11.91 undefined
201415.11 undefined9.34 undefined7.35 undefined
20136.61 undefined2.71 undefined1.81 undefined
20126.13 undefined2.53 undefined1.64 undefined
20115.31 undefined2.45 undefined1.77 undefined
20104.55 undefined2.37 undefined1.66 undefined
20093.75 undefined1.92 undefined1.41 undefined
20082.78 undefined1.4 undefined1.03 undefined
20072.19 undefined1.12 undefined0.82 undefined
20061.65 undefined0.89 undefined-0.65 undefined
20051.07 undefined0.59 undefined0.43 undefined

Gilead Sciences business model

Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences is one of the most popular companies on Eulerpool.com.

Gilead Sciences SWOT Analysis

Strengths

Gilead Sciences Inc has several notable strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a strong portfolio of innovative and high-quality drugs, particularly in the fields of antiviral and antifungal medications. These products have gained considerable recognition and have established Gilead Sciences as a trusted name in the industry.

Another strength of Gilead Sciences Inc lies in its robust research and development capabilities. The company invests heavily in scientific advancements and clinical trials, allowing them to discover breakthrough treatments and maintain a competitive edge. This commitment to innovation has resulted in numerous successful drug launches and a strong pipeline for future growth.

Weaknesses

Despite its strengths, Gilead Sciences Inc faces certain weaknesses that it needs to address. One aspect is its heavy reliance on a limited number of key products for a significant portion of its revenue. This creates a vulnerability to fluctuations in demand or potential patent expirations, which could impact the company's financial performance.

Additionally, Gilead Sciences has faced criticism for the high cost of some of its medications, particularly those treating chronic conditions such as HIV. The pricing strategy has led to public scrutiny and potential challenges in terms of affordability and accessibility for patients. Addressing these concerns could help improve the company's reputation and customer relationships.

Opportunities

Gilead Sciences Inc has several opportunities to further expand its market presence and generate growth. One major opportunity lies in the emerging markets, where there is a growing demand for pharmaceutical products. By tapping into these regions and adapting their business strategies accordingly, Gilead Sciences can extend its reach and increase its market share.

The company also has the opportunity to explore potential partnerships or collaborations with other pharmaceutical firms or research institutions. Such alliances can lead to knowledge sharing, joint development of new drugs, and shared resources, ultimately enhancing Gilead Sciences' product offerings and competitive advantage.

Threats

Gilead Sciences Inc faces certain threats that could hinder its growth and profitability. One prominent threat is the intense competition within the pharmaceutical industry. Rival companies continuously strive to innovate and launch similar products, thereby reducing Gilead Sciences' market share and pricing power.

Moreover, regulatory and legal challenges present additional threats. Strict regulations, patent disputes, and changes in healthcare policies can impact the company's ability to market and distribute its drugs effectively. To mitigate these threats, Gilead Sciences must continually adapt and comply with evolving regulations while safeguarding its intellectual property rights.

Gilead Sciences Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Gilead Sciences Revenue by Segment

Segmente202320222021202020192018
Product sales26.93 B USD26.98 B USD27.01 B USD24.36 B USD--
Biktarvy----4.74 B USD39 M USD
Genvoya----3.93 B USD794 M USD
Truvada----2.81 B USD260 M USD
Odefsey----1.66 B USD335 M USD
Sofosbuvir/Velpatasvir----1.97 B USD-
Descovy----1.5 B USD308 M USD
Royalty, contract and other revenues182 M USD299 M USD297 M USD334 M USD--
Complera/Eviplera----406 M USD327 M USD
Atripla----600 M USD131 M USD
Epclusa-----654 M USD
Ledipasvir/Sofosbuvir----643 M USD-
AmBisome----407 M USD229 M USD
Letairis----618 M USD-
Vemlidy----488 M USD12 M USD
Stribild----369 M USD97 M USD
Yescarta----456 M USD1 M USD
Revenue share - Symtuza----379 M USD52 M USD
Other(3)----285 M USD76 M USD
Vosevi----257 M USD78 M USD
Viread----243 M USD82 M USD
Ranexa----216 M USD-
Zydelig----103 M USD70 M USD
Harvoni-----144 M USD
Other HIV----47 M USD7 M USD

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Gilead Sciences Revenue by Segment

Segmente202320222021202020192018
Product sales----22.12 B USD3.7 B USD
Royalty, contract and other revenues----330 M USD450 M USD

Gilead Sciences Revenue by Region

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Gilead Sciences Revenue by Segment

DateEuropeOther InternationalU.S
20234.31 B USD3.37 B USD19.44 B USD
20224.47 B USD3.93 B USD18.88 B USD
20214.87 B USD3.16 B USD19.27 B USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Gilead Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Gilead Sciences historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Gilead Sciences shares outstanding

The number of shares was Gilead Sciences in 2024 — This indicates how many shares 1.255 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Gilead Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Gilead Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Gilead Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Gilead Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Gilead Sciences stock splits

In Gilead Sciences's history, there have been no stock splits.

Gilead Sciences dividend history and estimates

In 2024, Gilead Sciences paid a dividend amounting to 3.08 undefined. Dividend means that Gilead Sciences distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Gilead Sciences provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Gilead Sciences’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Gilead Sciences's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Gilead Sciences Dividend History

DateGilead Sciences Dividend
2030e59.96 undefined
2029e58.38 undefined
2028e51.66 undefined
2027e45.15 undefined
2026e52.04 undefined
2025e0.79 undefined
2015e0.43 undefined
2025e2.37 undefined
20243.08 undefined
20233 undefined
20222.92 undefined
20212.84 undefined
20202.72 undefined
20192.52 undefined
20182.28 undefined
20172.08 undefined
20161.84 undefined
2015e1.29 undefined

Gilead Sciences dividend payout ratio

In 2024, Gilead Sciences had a payout ratio of 363.48%. The payout ratio indicates the percentage of the company's profits that Gilead Sciences distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Gilead Sciences represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Gilead Sciences could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Gilead Sciences's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Gilead Sciences Payout Ratio History

DateGilead Sciences Payout ratio
2030e503.95 %
2029e526.42 %
2028e511.18 %
2027e474.25 %
2026e593.84 %
2025e465.44 %
2024363.48 %
2023952.61 %
202280.22 %
202157.61 %
20202,720 %
201959.72 %
201854.68 %
201759.43 %
201618.51 %
201510.83 %
2014952.61 %
2013952.61 %
2012952.61 %
2011952.61 %
2010952.61 %
2009952.61 %
2008952.61 %
2007952.61 %
2006952.61 %
2005952.61 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Gilead Sciences.

Gilead Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20252 2.01  (0.6 %)2025 Q2
3/31/20251.82 1.81  (-0.59 %)2025 Q1
12/31/20241.74 1.9  (9.39 %)2024 Q4
9/30/20241.59 2.02  (27.44 %)2024 Q3
6/30/20241.63 2.01  (23.18 %)2024 Q2
3/31/2024-1.52 -1.32  (13.32 %)2024 Q1
12/31/20231.79 1.72  (-4.16 %)2023 Q4
9/30/20231.96 2.29  (17.1 %)2023 Q3
6/30/20231.68 1.66  (-0.93 %)2023 Q2
3/31/20231.57 1.37  (-12.56 %)2023 Q1
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Gilead Sciences stock

Eulerpool World ESG Rating (EESG©)

84/ 100

🌱 Environment

82

👫 Social

83

🏛️ Governance

87

Environment

Scope 1 - Direct Emissions
56,096
Scope 2 - Indirect emissions from purchased energy
53,778
Scope 3 - Indirect emissions within the value chain
1,121,798
Total CO₂ emissions
109,874
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53
Percentage of women in management
Percentage of Asian employees38.1
Share of Asian management
Percentage of Hispanic/Latino employees12.8
Hispano/Latino Management share
Percentage of Black employees7.7
Black Management Share
Percentage of white employees37.7
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Gilead Sciences shareholders

%
Name
Stocks
Change
Date
9.46462 % The Vanguard Group, Inc.118,780,9971,872,8136/30/2025
5.64163 % BlackRock Institutional Trust Company, N.A.70,802,480138,8906/30/2025
4.71619 % State Street Global Advisors (US)59,188,160-335,5156/30/2025
4.28365 % Fidelity Management & Research Company LLC53,759,8392,549,2766/30/2025
3.68951 % Capital World Investors46,303,299-7,244,6026/30/2025
2.99048 % Wellington Management Company, LLP37,530,51010,171,5436/30/2025
2.47790 % Capital Research Global Investors31,097,679-23,512,6916/30/2025
2.45564 % Dodge & Cox30,818,322-1,876,4696/30/2025
2.32730 % Geode Capital Management, L.L.C.29,207,662727,5156/30/2025
2.03594 % Invesco Capital Management (QQQ Trust)25,551,107-148,9267/31/2025
1
2
3
4
5
...
10

Gilead Sciences Executives and Management Board

Mr. Daniel O'Day

(59)
Gilead Sciences Chairman of the Board, Chief Executive Officer (since 2019)
Compensation 22.61 M

Ms. Johanna Mercier

(54)
Gilead Sciences Chief Commercial Officer
Compensation 8.59 M

Mr. Andrew Dickinson

(54)
Gilead Sciences Chief Financial Officer
Compensation 8.11 M

Ms. Deborah Telman

(59)
Gilead Sciences Executive Vice President - Corporate Affairs, General Counsel
Compensation 5.27 M

Mr. Anthony Welters

(69)
Gilead Sciences Lead Independent Director
Compensation 444,921
1
2
3

Gilead Sciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
General Electric Company Stock
General Electric Company
SupplierCustomer0,900,76-0,120,450,49
Carna Biosciences Stock
Carna Biosciences
SupplierCustomer0,710,57-0,380,180,330,21
Galapagos NV Stock
Galapagos NV
SupplierCustomer0,53-0,24-0,080,77
Pfizer Inc. Stock
Pfizer Inc.
SupplierCustomer0,390,10-0,220,68-0,040,06
Veeva Systems Inc. Stock
Veeva Systems Inc.
SupplierCustomer0,340,29-0,560,730,620,28
GlobeImmune Stock
GlobeImmune
SupplierCustomer0,330,19-0,330,820,52
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,320,570,23-0,44-0,290,01
Dr. Reddy's Laboratories Ltd. Stock
Dr. Reddy's Laboratories Ltd.
SupplierCustomer0,31-0,09-0,600,740,57-0,09
Merck Stock
Merck
SupplierCustomer0,310,17-0,610,630,410,12
Novo Nordisk B Stock
Novo Nordisk B
SupplierCustomer0,290,55-0,03-0,58-0,500,02
1
2
3
4
5
...
7

Most common questions regarding Gilead Sciences

What values and corporate philosophy does Gilead Sciences represent?

Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.

In which countries and regions is Gilead Sciences primarily present?

Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.

What significant milestones has the company Gilead Sciences achieved?

Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.

What is the history and background of the company Gilead Sciences?

Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.

Who are the main competitors of Gilead Sciences in the market?

The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.

In which industries is Gilead Sciences primarily active?

Gilead Sciences Inc is primarily active in the pharmaceutical industry.

What is the business model of Gilead Sciences?

Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.

What is the P/E ratio of Gilead Sciences 2025?

The P/E ratio cannot be calculated for Gilead Sciences at the moment.

What is the P/S ratio of Gilead Sciences 2025?

The P/S cannot be calculated for Gilead Sciences currently.

What is the Quality Investing of Gilead Sciences?

The Quality Investing for Gilead Sciences is 3/10.

What is the revenue of Gilead Sciences 2025?

The expected Gilead Sciences revenue is 29.35 B USD.

How high is the profit of Gilead Sciences 2025?

The expected Gilead Sciences profit is 10.37 B USD.

What is the business model of Gilead Sciences

Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.

What is the Gilead Sciences dividend?

Gilead Sciences pays a dividend of 2.92 USD distributed over 4 payouts per year.

How often does Gilead Sciences pay dividends?

Gilead Sciences pays out a dividend 4 times a year.

What is the Gilead Sciences ISIN?

The ISIN of Gilead Sciences is US3755581036.

What is the Gilead Sciences WKN?

The WKN of Gilead Sciences is 885823.

What is the Gilead Sciences ticker?

The ticker of Gilead Sciences is GILD.

How much dividend does Gilead Sciences pay?

Over the past 12 months, Gilead Sciences paid a dividend of 3.08 USD . This corresponds to a dividend yield of about . For the coming 12 months, Gilead Sciences is expected to pay a dividend of 52.04 USD.

What is the dividend yield of Gilead Sciences?

The current dividend yield of Gilead Sciences is .

When does Gilead Sciences pay dividends?

Gilead Sciences pays a quarterly dividend. This is distributed in the months of January, April, July, October.

How secure is the dividend of Gilead Sciences?

Gilead Sciences paid dividends every year for the past 16 years.

What is the dividend of Gilead Sciences?

For the upcoming 12 months, dividends amounting to 52.04 USD are expected. This corresponds to a dividend yield of 46.32 %.

In which sector is Gilead Sciences located?

Gilead Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gilead Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gilead Sciences from 9/29/2025 amounting to 0.79 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2025.

When did Gilead Sciences pay the last dividend?

The last dividend was paid out on 9/29/2025.

What was the dividend of Gilead Sciences in the year 2024?

In the year 2024, Gilead Sciences distributed 3 USD as dividends.

In which currency does Gilead Sciences pay out the dividend?

The dividends of Gilead Sciences are distributed in USD.

All fundamentals about Gilead Sciences

Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.